drugset
drugset / Trial / NCT00650806

A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes

NCT00650806 ↗

Phase 2 Completed 376 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to test the safety and effectiveness of JNJ-28431754 in promoting weight loss in patients who are overweight or obese and who do not have diabetes.

Timeline

Start
2008-05
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 50 mg Oral
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 100 mg Oral
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 300 mg Oral

Indications

obesity disorder